Four Considerations for Improving Tech Transfer Processes
May 31, 2022
Many drug developers and biotechs rely on outsourcing to contract development and manufacturing companies (CDMOs) to scale up production processes while maintaining regulatory compliance. The success of these transfers depends on careful consideration of four key factors, according to a Bioprocess Online article by Lei Zheng. The first consideration is the geographic footprint of the operation.
According to Zheng, “An understanding of the market landscape requires more than securing global market manufacturing capacity — that is just a tactical consideration. Your manufacturing partner should understand the terrain of your campaign and the landscape of your entire drug marketing strategy.”
To learn more, click here.
(Source: Bioprocess Online, May 31st, 2022)
Tags: HEOR, CDMO, Biotech, Pharma